Target intelligence / Profile preview

Metabotropic glutamate receptor 3 (mGluR3) (mGluR3)

Target
mGluR3
Molecular classification
G protein-coupled receptor, Receptor
01

Overview

Metabotropic glutamate receptor 3 (mGluR3), encoded by the GRM3 gene, is a Class C G protein-coupled receptor that is negatively coupled to adenylate cyclase via Gi/Go proteins. It is widely expressed in the central nervous system, particularly in neurons and astrocytes, where it acts as an inhibitory autoreceptor and heteroceptor to regulate extracellular glutamate levels and synaptic plasticity. In primates, mGluR3 is also localized postsynaptically in the prefrontal cortex, where it plays a critical role in supporting higher cognitive functions such as working memory.\n\nGenetic variations and deficits in GRM3 signaling are strongly associated with psychiatric and cognitive disorders, most notably schizophrenia, bipolar disorder, and major depressive disorder. Pharmacological modulation of mGluR3 using agonists, antagonists, or allosteric modulators represents a promising therapeutic strategy for neuropsychiatric conditions and neurodegenerative diseases like Alzheimer's and Parkinson's. Additionally, emerging research highlights mGluR3 as a potential target in oncology, particularly in glioblastoma, where its inhibition can disrupt tumor cell self-renewal and promote differentiation.

Other names
mGlu3MGLUR3GLUR3GPRC1CGlutamate metabotropic receptor 3
02

Mechanism of action

Agonist, antagonist, negative allosteric modulator, or positive allosteric modulator of metabotropic glutamate receptor 3

03

Biological functions

Signal transductionSynaptic plasticityNeuroprotectionInhibition of adenylate cyclase activity
04

Disease associations

SchizophreniaBipolar disorderMajor depressive disorderCognitive impairmentGlioblastomaAlzheimer's diseaseParkinson's diseaseAnxiety disorderAlcoholism
05

Safety considerations

Lack of subtype selectivity and cross-reactivity with mGluR2High placebo response in clinical trialsPotential for psychiatric side effects or cognitive disruption due to altered glutamatergic transmissionDifficulty in translating rodent efficacy to humans due to species-specific expression differences (e.g., postsynaptic localization in primate cortex vs. presynaptic in rodents)
06

Interacting drugs

7 more in the full profile.

07

Biomarkers

GRM3 gene polymorphisms (e.g., rs1468412, rs6465084, rs12704290)EAAT2 expression levelsNAAG levels in cerebrospinal fluidFOLH1 genotype (e.g., rs202676)

Beyond the preview

Go deeper on Metabotropic glutamate receptor 3 (mGluR3) (mGluR3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Metabotropic glutamate receptor 3 (mGluR3) (mGluR3).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call